These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 33764538

  • 1. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
    Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Cheng S, Numachi Y, Peng C, Xue F, Mikol DD.
    Headache; 2021 Apr; 61(4):653-661. PubMed ID: 33764538
    [Abstract] [Full Text] [Related]

  • 2. Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial.
    Hirata K, Takeshima T, Sakai F, Numachi Y, Yoshida R, Koukakis R, Hasebe M, Yui D, da Silva Lima GP, Cheng S.
    BMJ Open; 2023 Aug 18; 13(8):e068616. PubMed ID: 37597868
    [Abstract] [Full Text] [Related]

  • 3. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
    Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD.
    Headache; 2021 Jun 18; 61(6):927-935. PubMed ID: 34153117
    [Abstract] [Full Text] [Related]

  • 4. Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
    Ashina M, Tepper SJ, Brandes JL, Reuter U, Boudreau GP, Weatherall M, Gantenbein AR, Doležil D, Klatt J, Wang A, Karanam AK, Cheng S, Mikol DD.
    Headache; 2022 May 18; 62(5):624-633. PubMed ID: 35593783
    [Abstract] [Full Text] [Related]

  • 5. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.
    Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Wright IK, Chou DE, Klatt J, Picard H, Lenz RA, Mikol DD.
    Neurology; 2020 Aug 04; 95(5):e469-e479. PubMed ID: 32636324
    [Abstract] [Full Text] [Related]

  • 6. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
    Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Lenz R, Wang Y, Cheng S, Hirama T, Mikol DD.
    Headache; 2019 Nov 04; 59(10):1731-1742. PubMed ID: 31612482
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study.
    Ferrari MD, Reuter U, Goadsby PJ, Paiva da Silva Lima G, Mondal S, Wen S, Tenenbaum N, Pandhi S, Lanteri-Minet M, Stites T.
    J Neurol Neurosurg Psychiatry; 2022 Mar 04; 93(3):254-262. PubMed ID: 34845002
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of erenumab in women with a history of menstrual migraine.
    Pavlovic JM, Paemeleire K, Göbel H, Bonner J, Rapoport A, Kagan R, Zhang F, Picard H, Mikol DD.
    J Headache Pain; 2020 Aug 03; 21(1):95. PubMed ID: 32746775
    [Abstract] [Full Text] [Related]

  • 10. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
    Tepper SJ, Ashina M, Reuter U, Hallström Y, Broessner G, Bonner JH, Picard H, Cheng S, Chou DE, Zhang F, Klatt J, Mikol DD.
    J Headache Pain; 2021 Jul 23; 22(1):81. PubMed ID: 34301173
    [Abstract] [Full Text] [Related]

  • 11. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
    Tepper SJ, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein SD, Winner P, Zhang F, Cheng S, Mikol DD.
    Cephalalgia; 2020 May 23; 40(6):543-553. PubMed ID: 32216456
    [Abstract] [Full Text] [Related]

  • 12. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, Salerno A, Torelli P, Albanese M, Carnevale A, Bono F, D'Amico D, Filippi M, Altamura C, Vernieri F, EARLY Study Group.
    Headache; 2021 Oct 23; 61(9):1351-1363. PubMed ID: 34309862
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J.
    Lancet; 2018 Nov 24; 392(10161):2280-2287. PubMed ID: 30360965
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis.
    Kitamura S, Takeshima T, Yui D, da Silva Lima GP, Koukakis R, Peng C, Yoshida R, Numachi Y, Hasebe M.
    Neurol Ther; 2023 Dec 24; 12(6):1993-2006. PubMed ID: 37698837
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Assessment of prolonged safety and tolerability of erenumab in migraine patients in a long-term open-label study (APOLLON).
    Göbel H, Schlegel E, Jaeger K, Ortler S, Leist L.
    J Headache Pain; 2024 Sep 25; 25(1):157. PubMed ID: 39322961
    [Abstract] [Full Text] [Related]

  • 17. A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
    Yu S, Kim BK, Wang H, Zhou J, Wan Q, Yu T, Lian Y, Arkuszewski M, Ecochard L, Wen S, Yin F, Li Z, Su W, Wang SJ.
    J Headache Pain; 2022 Nov 21; 23(1):146. PubMed ID: 36404301
    [Abstract] [Full Text] [Related]

  • 18. The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response.
    Broessner G, Reuter U, Bonner JH, Dodick DW, Hallström Y, Picard H, Zhang F, Lenz RA, Klatt J, Mikol DD.
    Headache; 2020 Oct 21; 60(9):2026-2040. PubMed ID: 32851644
    [Abstract] [Full Text] [Related]

  • 19. Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
    Tepper SJ, Lipton RB, Silberstein SD, Kudrow D, Ashina M, Reuter U, Dodick DW, Wang A, Cheng S, Klatt J, Mikol DD.
    Headache; 2023 Jun 21; 63(6):730-742. PubMed ID: 37313616
    [Abstract] [Full Text] [Related]

  • 20. Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study.
    Wang SJ, Roxas AA, Saravia B, Kim BK, Chowdhury D, Riachi N, Tai MS, Tanprawate S, Ngoc TT, Zhao YJ, Mikol DD, Pandhi S, Wen S, Mondal S, Tenenbaum N, Hours-Zesiger P.
    Cephalalgia; 2021 Nov 21; 41(13):1285-1297. PubMed ID: 34171973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.